Phase 4 — Post-approval study. The treatment has been approved, but researchers continue monitoring it in a large population over time.
Trial locations(20 sites)
China
Novartis Investigative Site, Hefei, Anhui Novartis Investigative Site, Fuzhou, Fujian Novartis Investigative Site, Guangzhou, Guangdong Novartis Investigative Site, Guangzhou, Guangdong Novartis Investigative Site, Guangzhou, Guangdong Novartis Investigative Site, Shenzhen, Guangdong Novartis Investigative Site, Zunyi, Guizhou Novartis Investigative Site, Harbin, Heilongjiang Novartis Investigative Site, Zhengzhou, Henan Novartis Investigative Site, Wuhan, Hubei Novartis Investigative Site, Nanchang, Jiangxi Novartis Investigative Site, Changchun, Jilin Novartis Investigative Site, Dalian, Liaoning Novartis Investigative Site, Jining, Shandong Novartis Investigative Site, Xian, Shanxi Novartis Investigative Site, Chengdu, Sichuan Novartis Investigative Site, Wenzhou, Zhejiang Novartis Investigative Site, Beijing Novartis Investigative Site, Lanzhou Novartis Investigative Site, Tianjin